Assessment of the efficacy of passive cellular immunotherapy for glioma patients

References

Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T.L., Diouf, O., Wakefield, A., et al. (2017). HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma. JAMA Oncol. 3, 1094–1101.10.1001/jamaoncol.2017.0184Suche in Google Scholar PubMed PubMed Central

Ammirati, M., Galicich, J.H., Arbit, E., and Liao, Y. (1987). Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21, 607–614.10.1227/00006123-198711000-00001Suche in Google Scholar PubMed

Artene, S.-A., Turcu-Stiolica, A., Ciurea, M.E., Folcuti, C., Tataranu, L.G., Alexandru, O., Purcaru, O.S., Tache, D.E., Boldeanu, M.V., Silosi, C., et al. (2018). Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials. Sci. Rep. 8, 1–10.10.1038/s41598-018-30296-xSuche in Google Scholar PubMed PubMed Central

Avril, T., Vauleon, E., Tanguy-Royer, S., Mosser, J., and Quillien, V. (2011). Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 3, 42–44.10.2217/imt.11.39Suche in Google Scholar PubMed

Barba, D., Saris, S.C., Holder, C., Rosenberg, S.A., and Oldfield, E.H. (1989). Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70, 175–182.10.3171/jns.1989.70.2.0175Suche in Google Scholar PubMed

Blancher, A., Roubinet, F., Grancher, A.S., Tremoulet, M., Bonaté, A., Delisle, M.B., Calot, J.P., Pourreau, C., Franks, C., and Ducos, J. (1993). Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur. Cytokine Netw. 4, 331–341.Suche in Google Scholar

Boiardi, A., Silvani, A., Ruffini, P.A., Rivoltini, L., Parmiani, G., Broggi, G., and Salmaggi, A. (1994). Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 39, 193–197.10.1007/BF01533386Suche in Google Scholar PubMed

Brody, J., Kohrt, H., Marabelle, A., and Levy, R. (2011). Active and passive immunotherapy for lymphoma: proving principles and improving results. J. Clin. Oncol. 29, 1864–1875.10.1200/JCO.2010.33.4623Suche in Google Scholar PubMed

Brown, C.E., Badie, B., Barish, M.E., Weng, L., Ostberg, J.R., Chang, W.C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015). Bioactivity and safety of IL13R 2-redirected chimeric antigen receptor CD8⁺ T cells in patients with recurrent glioblastoma. Clin. Cancer Res. 21, 4062–4072.10.1158/1078-0432.CCR-15-0428Suche in Google Scholar PubMed PubMed Central

Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Blanchard, M.S., Kilpatrick, J., Simpson, J., et al. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569.10.1056/NEJMoa1610497Suche in Google Scholar PubMed PubMed Central

Cao, J.-X., Zhang, X.-Y., Liu, J.-L., Li, D., Li, J.-L., Liu, Y.-S., Wang, M., Xu, B.-L., Wang, H.-B., and Wang, Z.-X. (2014). Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One 9, e107173.10.1371/journal.pone.0107173Suche in Google Scholar PubMed PubMed Central

Choi, B.D., Suryadevara, C.M., Gedeon, P.C., Herndon Ii, J.E., Sanchez-Perez, L., Bigner, D.D., and Sampson, J.H. (2014). Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J. Clin. Neurosci. 21, 189–190.10.1016/j.jocn.2013.03.012Suche in Google Scholar

Chow, K.K.H., Naik, S., Kakarla, S., Brawley, V.S., Shaffer, D.R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013). T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21, 629–637.10.1038/mt.2012.210Suche in Google Scholar

Chung, D.-S., Shin, H.-J., and Hong, Y.-K. (2014). A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J. Immunol. Res. 2014, 1–16.10.1155/2014/326545Suche in Google Scholar

Crough, T., Beagley, L., Smith, C., Jones, L., Walker, D.G., and Khanna, R. (2012). Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol. Cell. Biol. 90, 872–880.10.1038/icb.2012.19Suche in Google Scholar

Dillman, R.O., Duma, C.M., Schiltz, P.M., DePriest, C., Ellis, R.A., Okamoto, K., Beutel, L.D., De Leon, C., and Chico, S. (2004). Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother. 27, 398–404.10.1097/00002371-200409000-00009Suche in Google Scholar

Dillman, R.O., Duma, C.M., Ellis, R.A., Cornforth, A.N., Schiltz, P.M., Sharp, S.L., and DePriest, M.C. (2009). Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J. Immunother. 32, 914–919.10.1097/CJI.0b013e3181b2910fSuche in Google Scholar

Dixit, S. (2014). Immunotherapy for high-grade glioma. Future Oncol. 10, 911–915.10.2217/fon.14.20Suche in Google Scholar

Ghazi, A., Ashoori, A., Hanley, P.J., Brawley, V.S., Shaffer, D.R., Kew, Y., Powell, S.Z., Grossman, R., Grada, Z., Scheurer, M.E., et al. (2012). Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J. Immunother. 35, 159–168.10.1097/CJI.0b013e318247642fSuche in Google Scholar

Hanaei, S., Afshari, K., Hirbod-Mobarakeh, A., Mohajer, B., Amir Dastmalchi, D., and Rezaei, N. (2018). Therapeutic efficacy of specific immunotherapy for glioma: a systematic review and meta-analysis. Rev. Neurosci. 29, 443–461.10.1515/revneuro-2017-0057Suche in Google Scholar

Hayes, R.L., Koslow, M., Hiesiger, E.M., Hymes, K.B., Hochster, H.S., Moore, E.J., Pierz, D.M., Chen, D.K., Budzilovich, G.N., and Ransohoff, J. (1995). Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76, 840–852.10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-RSuche in Google Scholar

Hayes, R.L., Arbit, E., Odaimi, M., Pannullo, S., Scheff, R., Kravchinskiy, D., and Zaroulis, C. (2001). Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit. Rev. Oncol. Hematol. 39, 31–42.10.1016/S1040-8428(01)00122-6Suche in Google Scholar

Hegde, M., Corder, A., Chow, K.K.H., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y.J., Baskin, D.S., Merchant, F.A., Brawley, V.S., et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087–2101.10.1038/mt.2013.185Suche in Google Scholar PubMed PubMed Central

Hervey-Jumper, S.L. and Berger, M.S. (2014). Reoperation for recurrent high-grade glioma. Neurosurgery. 75, 491–499.10.1227/NEU.0000000000000486Suche in Google Scholar PubMed

Holladay, F.P., Heitz-Turner, T., Bayer, W.L., and Wood, G.W. (1992). Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J. Neurosurg. 77, 757–762.10.3171/jns.1992.77.5.0757Suche in Google Scholar PubMed

Holladay, F.P., Heitz-Turner, T., Bayer, W.L., and Wood, G.W. (1996). Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. J. Neurooncol. 27, 179–189.10.1007/BF00177482Suche in Google Scholar PubMed

Hongquan, N., Zhen, D., Fangyong, D., Tao, Z., Ting, L., and Delin, X. (2004). Experimental and clinical research of dendritic cell and syngeneic immunotherapy of brain glioma. Chin German J. Clin. Oncol. 3, 147–150.10.1007/s10330-003-0189-5Suche in Google Scholar

Ingram, M., Shelden, C.H., Jacques, S., Skillen, R.G., Bradley, W.G., Techy, G.B., Freshwater, D.B., Abts, R.M., and Rand, R.W. (1987). Preliminary clinical trial of immunotherapy for malignant glioma. J. Biol. Response Mod. 6, 489–498.Suche in Google Scholar

Ishikawa, E., Tsuboi, K., Saijo, K., Harada, H., Takano, S., Nose, T., and Ohno, T. (2004). Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24, 1861–1871.Suche in Google Scholar

Ishikawa, E., Takano, S., Ohno, T., and Tsuboi, K. (2012). Adoptive cell transfer therapy for malignant gliomas. Adv. Exp. Med. Biol. 746, 109–120.10.1007/978-1-4614-3146-6_9Suche in Google Scholar PubMed

Jacobs, S.K., Wilson, D.J., Kornblith, P.L., and Grimm, E.A. (1986). Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 46, 2101–2104.10.3171/jns.1986.64.5.0743Suche in Google Scholar

Jeffes 3rd, E.W., Beamer, Y.B., Jacques, S., Silberman, R.S., Vayuvegula, B., Gupta, S., Coss, J.S., Yamamoto, R.S., and Granger, G.A. (1993). Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J. Neurooncol. 15, 141–155.10.1007/BF01053935Suche in Google Scholar PubMed

Kitahara, T., Watanabe, O., Yamaura, A., Makino, H., Watanabe, T., Suzuki, G., and Okumura, K. (1987). Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J. Neurooncol. 4, 329–336.10.1007/BF00195603Suche in Google Scholar PubMed

Kong, D.S., Nam, D.H., Kang, S.H., Lee, J.W., Chang, J.H., Kim, J.H., Lim, Y.J., Koh, Y.C., Chung, Y.G., Kim, J.M., et al. (2017). Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget. 8, 7003–7013.10.18632/oncotarget.12273Suche in Google Scholar PubMed PubMed Central

Kruse, C.A., Cepeda, L., Owens, B., Johnson, S.D., Stears, J., and Lillehei, K.O. (1997). Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45, 77–87.10.1007/s002620050405Suche in Google Scholar

Lamb, L.S., Bowersock, J., Dasgupta, A., Gillespie, G.Y., Su, Y., Johnson, A., and Spencer, H.T. (2013). Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS One 8, e51805.10.1371/journal.pone.0051805Suche in Google Scholar

Lillehei, K.O., Mitchell, D.H., Johnson, S.D., McCleary, E.L., and Kruse, C.A. (1991). Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28, 16–23.10.1227/00006123-199101000-00003Suche in Google Scholar

Marchi, N., Teng, Q., Nguyen, M.T., Franic, L., Desai, N.K., Masaryk, T., Rasmussen, P., Trasciatti, S., and Janigro, D. (2010). Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity. BMC Neurosci. 11, 34.10.1186/1471-2202-11-34Suche in Google Scholar

Merchant, R.E., Grant, A.J., Merchant, L.H., and Young, H.F. (1988). Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62, 665–671.10.1002/1097-0142(19880815)62:4<665::AID-CNCR2820620403>3.0.CO;2-OSuche in Google Scholar

Nagasawa, D.T., Fong, C., Yew, A., Spasic, M., Garcia, H.M., Kruse, C.A., and Yang, I. (2012). Passive immunotherapeutic strategies for the treatment of malignant gliomas. Neurosurg. Clin. N. Am. 23, 481–495.10.1016/j.nec.2012.04.008Suche in Google Scholar

Ogbomo, H., Cinatl, J., Mody, C.H., and Forsyth, P.A. (2011). Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol. Med. 17, 433–441.10.1016/j.molmed.2011.03.004Suche in Google Scholar

Okamoto, Y., Shimizu, K., Tamura, K., Miyao, Y., Yamada, M., Matsui, Y., Tsuda, N., Takimoto, H., Hayakawa, T., and Mogami, H. (1988). An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir. (Vienna) 94, 47–52.10.1007/BF01406615Suche in Google Scholar

O’Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K., Morrissette, J.J.D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984.10.1126/scitranslmed.aaa0984Suche in Google Scholar

Plautz, G.E., Barnett, G.H., Miller, D.W., Cohen, B.H., Prayson, R.A., Krauss, J.C., Luciano, M., Kangisser, D.B., and Shu, S. (1998). Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89, 42–51.10.3171/jns.1998.89.1.0042Suche in Google Scholar

Plautz, G.E., Miller, D.W., Barnett, G.H., Stevens, G.H., Maffett, S., Kim, J., Cohen, P.A., and Shu, S. (2000). T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6, 2209–2218.Suche in Google Scholar

Quattrocchi, K.B., Miller, C.H., Cush, S., Bernard, S.A., Dull, S.T., Smith, M., Gudeman, S., and Varia, M.A. (1999). Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45, 141–157.10.1023/A:1006293606710Suche in Google Scholar

Rodriguez, A., Brown, C., and Badie, B. (2017). Chimeric antigen receptor T-cell therapy for glioblastoma. Transl. Res. 187, 93–102.10.1016/j.trsl.2017.07.003Suche in Google Scholar PubMed

Ruzevick, J., Jackson, C., Phallen, J., and Lim, M. (2012). Clinical trials with immunotherapy for high-grade glioma. Neurosurg. Clin. N. Am. 23, 459–470.10.1016/j.nec.2012.04.003Suche in Google Scholar PubMed

Ryu, J.I., Han, M.H., Cheong, J.H., Kim, J.M., and Kim, C.H. (2017). Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas. Immunotherapy 9, 411–421.10.2217/imt-2017-0003Suche in Google Scholar PubMed

Sankhla, S.K., Nadkarni, J.S., and Bhagwati, S.N. (1995). Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J. Neurooncol. 27, 133–140.10.1007/BF00177476Suche in Google Scholar PubMed

Schuessler, A., Smith, C., Beagley, L., Boyle, G.M., Rehan, S., Matthews, K., Jones, L., Crough, T., Dasari, V., Klein, K., et al. (2014). Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74, 3466–3476.10.1158/0008-5472.CAN-14-0296Suche in Google Scholar PubMed

Sloan, A.E., Dansey, R., Zamorano, L., Barger, G., Hamm, C., Diaz, F., Baynes, R., and Wood, G. (2000). Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg. Focus 9, e9.10.3171/foc.2000.9.6.10Suche in Google Scholar PubMed

Smith, M.M., Thompson, J.E., Castillo, M., Cush, S., Mukherji, S.K., Miller, C.H., and Quattrocchi, K.B. (1996). MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am. J. Neuroradiol. 17, 1065–1071.Suche in Google Scholar

Tsuboi, K., Saijo, K., Ishikawa, E., Tsurushima, H., Takano, S., Morishita, Y., and Ohno, T. (2003). Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9, 3294–3302.Suche in Google Scholar

Tsurushima, H., Liu, S.Q., Tuboi, K., Matsumura, A., Yoshii, Y., Nose, T., Saijo, K., and Ohno, T. (1999). Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. Jpn. J. Cancer Res. 90, 536–545.10.1111/j.1349-7006.1999.tb00781.xSuche in Google Scholar PubMed PubMed Central

Vaquero, J., Martínez, R., Ramiro, J., Salazar, F.G., Barbolla, L., and Regidor, C. (1991). Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study. Acta Neurochir. (Vienna) 109, 42–45.10.1007/BF01405696Suche in Google Scholar PubMed

Vatu, B.I., Artene, S.-A., Staicu, A.-G., Turcu-Stiolica, A., Folcuti, C., Dragoi, A., Cioc, C., Baloi, S.-C., Tataranu, L.G., Silosi, C., et al. (2018). Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review. J. Immunoassay Immunochem. 40, 70–80.10.1080/15321819.2018.1551804Suche in Google Scholar PubMed

Wang, X., Zhao, H.-Y., Zhang, F.-C., Sun, Y., Xiong, Z.-Y., and Jiang, X.-B. (2014). Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review. Cancer Invest. 32, 451–457.10.3109/07357907.2014.958234Suche in Google Scholar

Weller, M., Butowski, N., Tran, D.D., Recht, L.D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S.A., Iwamoto, F., et al. (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385.10.1016/S1470-2045(17)30517-XSuche in Google Scholar

Wood, G.W., Holladay, F.P., Turner, T., Wang, Y.Y., and Chiga, M. (2000). A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J. Neurooncol. 48, 113–120.10.1023/A:1006456421177Suche in Google Scholar

Yoshida, S., Tanaka, R., Takai, N., and Ono, K. (1988). Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 48, 5011–5016.Suche in Google Scholar